市场调查报告书
商品编码
1496719
抗体治疗市场:按形式、给药途径、来源、疾病领域和最终用户分类 - 全球预测 2024-2030Antibody Therapeutics Market by Format (Antibody Fragment, Bispecific Antibody, Monoclonal Antibody), Route of Administration (Intravenous, Subcutaneous), Source, Disease Areas, End User - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
预计2023年抗体治疗市场规模为2,487.9亿美元,预计2024年将达2,857.7亿美元,2030年将达6,575亿美元,复合年增长率为14.89%。
抗体疗法是一组使用抗体来模拟或增强免疫系统对抗疾病的能力的治疗方法。抗体疗法的高精度使得客製化治疗能够提供比传统药物更高的特异性和更低的毒性,使其能够有效治疗包括癌症、自体免疫疾病和感染疾病。慢性病的增加和全球医疗保健支出的增加导致抗体疗法的采用增加。然而,高昂的开发成本以及漫长而复杂的监管核准限制了抗体疗法的普及。然而,医疗技术的进步提高了抗体的生产效率。此外,新一代抗体的出现以及政府对癌症治疗和护理的支持倡议预计将为抗体治疗市场提供潜在机会。
主要市场统计 | |
---|---|
基准年[2023] | 2487.9亿美元 |
预测年份 [2024] | 2857.7亿美元 |
预测年份 [2030] | 6575亿美元 |
复合年增长率(%) | 14.89% |
区域洞察
在美洲,抗体治疗市场在完善的研发生态系统、广泛的专利组合和高医疗保健支出的支持下呈现强劲成长。此外,美洲是许多主要生物製药公司的所在地,这些公司正在投入大量资源来开发单株抗体和新药。在亚太地区,由于医疗基础设施的成长和慢性病的增加,对抗体治疗的需求激增。此外,由于强大的研究机构和支持性政府政策的支持,个人化医疗和抗体开发取得了进步,亚太地区的抗体治疗市场正在成长。欧盟 (EU) 国家拥有强大的製药工业、广泛的研究计画和全面的智慧财产权框架,对抗体治疗领域至关重要。此外,中东和非洲国家正在投资最先进的医疗设施和医疗保健创新。
FPNV定位矩阵
FPNV 定位矩阵对于评估供应商在抗体治疗市场的定位至关重要。此矩阵提供了对供应商的全面评估,并检验了与业务策略和产品满意度相关的关键指标。这种详细的评估使用户能够根据自己的要求做出明智的决定。根据评估结果,供应商被分为代表其成功程度的四个像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可以对抗体治疗市场供应商的现状进行深入而详细的评估。透过仔细比较和分析供应商的贡献,您可以更深入地了解每个供应商的绩效以及他们在争夺市场占有率时面临的挑战。这些贡献包括整体收益、客户群和其他关键指标。此外,该分析还提供了对该行业竞争性质的宝贵见解,包括在研究基准年期间观察到的累积、分散主导地位和合併特征等因素。有了这些详细信息,供应商可以做出更明智的决策并製定有效的策略,以在市场竞争中保持领先地位。
策略分析与建议
策略分析对于寻求在全球市场站稳脚跟的组织至关重要。对抗体治疗市场当前地位的全面评估使公司能够做出符合其长期愿望的明智决策。此关键评估涉及对组织的资源、能力和整体绩效进行彻底分析,以确定核心优势和需要改进的领域。
[197 Pages Report] The Antibody Therapeutics Market size was estimated at USD 248.79 billion in 2023 and expected to reach USD 285.77 billion in 2024, at a CAGR 14.89% to reach USD 657.50 billion by 2030.
Antibody therapeutics are a class of medical treatments that employ antibodies to mimic or enhance the immune system's ability to fight diseases. The precision of antibody therapeutics allows for tailored treatments that provide high specificity and lower toxicity profiles than conventional drugs, making them effective in treating various conditions, including cancers, autoimmune diseases, and infectious diseases. The increasing incidences of chronic diseases and increased healthcare expenditure globally have increased the adoption of antibody therapeutics. However, high costs associated with development and lengthy and complex regulatory approvals limit the penetration of antibody therapeutics. Nevertheless, advancements in medical technology are leading to more productive antibody production. In addition, the emergence of next-generation antibodies and supportive government initiatives for cancer care and treatments are expected to offer potential opportunities for the antibody therapeutics market.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 248.79 billion |
Estimated Year [2024] | USD 285.77 billion |
Forecast Year [2030] | USD 657.50 billion |
CAGR (%) | 14.89% |
Regional Insights
In the Americas, antibody therapeutics market exhibit robust growth supported by a well-established R&D ecosystem, extensive patent portfolio, and high healthcare expenditure. Furthermore, the Americas includes numerous biopharmaceutical giants, which dedicate substantial resources to developing monoclonal antibodies and novel drug discovery. The Asia-Pacific region experienced a surge in the need for antibody therapeutics due to a growing healthcare infrastructure and increased incidences of chronic disease. Moreover, the Asia-Pacific region is witnessing growth in the antibody therapeutics market owing to the advances in personalized medicine and antibody development, supported by its strong research institutions and supportive government policies. Given their strong pharmaceutical industry, extensive research initiatives, and comprehensive intellectual property rights framework, European Union countries are pivotal in the antibody therapeutics landscape. In addition, countries in the Middle East and Africa are investing in state-of-the-art medical facilities and healthcare innovation.
Market Insights
The market dynamics represent an ever-changing landscape of the Antibody Therapeutics Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Antibody Therapeutics Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Antibody Therapeutics Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
SystImmune and Bristol Myers Squibb Announce a Global Strategic Collaboration Agreement for the Development and Commercialization of BL-B01D1
SystImmune entered into a pivotal license and collaboration agreement with Bristol Myers Squibb that focuses on the co-development and commercialization of the innovative BL-B01D1, an EGFRxHER3 bispecific antibody-drug conjugate (ADC) that is promising as a first-in-class therapy. Currently undergoing a Phase 1 clinical trial targeting non-small cell lung cancer (NSCLC), BL-B01D1 has already exhibited significant anti-tumor activity and a well-managed safety profile across various solid tumors. [Published On: 2023-12-11]
AbbVie and BigHat Biosciences Announce Research Collaboration to Leverage Artificial Intelligence and Machine Learning to Discover Next-Generation Therapeutic Antibodies
AbbVie Inc. partnered with BigHat Biosciences to drive the creation of cutting-edge therapeutic antibodies for oncology and neuroscience. This collaboration aims to streamline the discovery and optimization of superior antibodies for several key therapeutic targets. This initiative reflects the company's dedication to integrating AI and ML advancements into the drug development workflow to expedite the delivery of effective treatments. [Published On: 2023-12-05]
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
AbbVie announced the acquisition of ImmunoGen, a significant development that includes control of rights of ELAHERE (mirvetuximab soravtansine-gynx), ImmunoGen's premier cancer therapy. This acquisition is a testament to AbbVie's commitment to expanding its solid tumor treatment capabilities, positioning it to better address the complexities of cancer care. [Published On: 2023-11-30]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Antibody Therapeutics Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Antibody Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AbCellera Biologics Inc., Adaptimmune Therapeutics PLC, ADC Therapeutics SA, Aenova Holding GmbH, Almac Group Limited, Amgen Inc., Antikor Biopharma, Argenx SE, Astellas Pharma Inc., AstraZeneca PLC, Baxter International Inc., Bayer AG, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Biogen Inc., BioNTech SE, Bristol-Myers Squibb Company, Confo Therapeutics, DH Life Sciences, LLC, DotBio Pte. Ltd., Eli Lilly and Company, Emergent BioSolutions Inc., Evonik Industries AG, F. Hoffmann-La Roche Ltd., GE HealthCare Technologies, Inc.,, Genmab A/S, GlaxoSmithKline PLC, Grifols, S.A., Incyte Corporation, iTeos Therapeutics, Inc., Johnson & Johnson Services, Inc., Merck KGaA, Merus N.V., MoonLake Immunotherapeutics AG, MorphoSys AG, Novartis AG, Novo Nordisk A/S, Numab Therapeutics AG, Pfizer Inc., PharmAbcine Inc., Pyxis Oncology, Inc., Regeneron Pharmaceuticals, Inc., SAB Biotherapeutics, Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific Inc., TRIO Pharmaceuticals Inc., UCB S.A., and Xencor, Inc..
Market Segmentation & Coverage